Developing a new treatment for pancreatic cancer using targeted drug delivery
Preclinical Development of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC)
This study is testing a new oral medication called ACXT-3102 that aims to specifically attack pancreatic cancer cells while being gentle on healthy cells, making treatment easier and more effective for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Accuronix Therapeutics, INC. NIH-funded |
| Lab location | 1 site (St. Louis, UNITED STATES) |
| Project ID | NIH-10435565 on NIH RePORTER |
What this research studies
This research focuses on creating a novel drug, ACXT-3102, specifically designed to target pancreatic cancer cells while minimizing side effects on healthy cells. The approach utilizes a unique mechanism that enhances the drug's effectiveness by binding it to a molecule that induces cancer cell death. By optimizing the drug's formulation for oral administration, the researchers aim to improve patient convenience and treatment outcomes. The study will involve collaboration with experts from Washington University to ensure thorough development and testing of this promising therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic adenocarcinoma who are seeking new treatment options.
Not a fit: Patients with other types of cancer or those who do not have pancreatic adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and less toxic treatment option for patients with pancreatic cancer.
How similar studies have performed: Previous research has shown promise in targeted drug delivery for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
St. Louis, UNITED STATES
- Accuronix Therapeutics, INC. — St. Louis, United States (Active)
Researchers
- Principal investigator: Keller, Bradley T. — Accuronix Therapeutics, INC.
- Study coordinator: Keller, Bradley T.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.